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Abstract
Background: To date, inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of
radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 (
90Y)-radio-conjugates of a monoclonal antibody,
which we showed previously to bind specifically to the abundant intracellular La ribonucleoprotein revealed in dead tumor
cells after DNA-damaging treatment.
Methodology/Principal Findings: Immunoconjugates of the DAB4 clone of the La-specific monoclonal antibody, APOMABH,
were prepared using the metal chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and then
radiolabeled with
90Y. Mice bearing established subcutaneous tumors were treated with
90Y-DOTA-DAB4 alone or after
chemotherapy. Non-radiosensitizing cyclophosphamide/etoposide chemotherapy was used for the syngeneic EL4 lymphoma
model. Radiosensitizing cisplatin/gemcitabine chemotherapy was used for the syngeneic Lewis Lung carcinoma (LL2) model,
and for the xenograft models of LNCaP prostatic carcinoma and Panc-1 pancreatic carcinoma. We demonstrate the safety,
specificity, and efficacy of
90Y-DOTA-DAB4-radioimmunotherapy alone or combined with chemotherapy. EL4 lymphoma-
bearing mice either were cured at higher doses of radioimmunotherapy alone or lower doses of radioimmunotherapy in
synergy with chemotherapy. Radioimmunotherapy alone was less effective in chemo- and radio-resistant carcinoma models.
However, radioimmunotherapy synergized with radiosensitizing chemotherapy to retard significantly tumor regrowth and so
prolong the survival of mice bearing LL2, LNCaP, or Panc-1 subcutaneous tumor implants.
Conclusions/Significance: We report proof-of-concept data supporting a unique form of radioimmunotherapy, which
delivers bystander killing to viable cancer cells after targeting the universal cancer antigen, La, created by DNA-damaging
treatment in neighboring dead cancer cells. Subsequently we propose that DAB4-targeted ionizing radiation induces
additional cycles of tumor cell death, which further augments DAB4 binding to produce a tumor-lethal ‘genotoxic chain
reaction’. Clinically, this approach may be useful as consolidation treatment after a drug-induced cell death among (small-
volume) metastatic deposits, the commonest cause of cancer death. This article is part II of a two-part series providing
proof-of-concept for the diagnostic and therapeutic use of the DAB4 clone of the La-specific monoclonal antibody,
APOMABH.
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Introduction
The therapeutic activity of monoclonal antibodies (mAb) may
be improved by arming them with additional effector mechanisms
[1] such as ionizing radiation that kills neighboring untargeted
tumor cells by bystander and/or radiation crossfire effects [2]. The
only US Food and Drug Administration (FDA)-approved radio-
immunotherapy (RIT) uses anti-CD20 monoclonal antibodies
(mAb) armed with
131I (tositumomab) or
90Y (ibritumomab
tiuxetan), which display clinical efficacy even in follicular non-
Hodgkin lymphoma (NHL) patients refractory to rituximab [3].
Notwithstanding the clinical utility of CD20-directed RIT for
rituximab-refractory NHL, the two approved products have had
limited commercial success perhaps because the niche indication
for their use necessarily restricts sales, and because the sheer
logistical complexity of their application attenuates their clinical
acceptance. Moreover, several factors curb the clinical utility of
radioimmunotherapy for metastatic carcinoma, which comprises a
more populous group of malignancies than lymphoma. Tumor-
related factors include radioresistance, and the heterogeneous and
low-level expression of target antigens that reduce tumor
accumulation of radioimmunoconjugates. Myelosuppression re-
mains the dose-limiting toxicity of radioimmunotherapy [3].
In spite of evasion of apoptosis being recognized as a hallmark of
cancer [4], dead cells remain a common feature of many
malignancies [5–7], and may increase in number after primary
chemotherapy [8,9]. For example, the only approved radioimmu-
notherapy for carcinomaworldwide is tumor necrosis therapy (TNT).
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131I-labeled chimeric IgG, which was approved by the
Chinese State Food and Drug Administration and which produced
an overall objective response rate of 34% among patients with
advanced lung cancer [2]. Unlike many radioimmunoconjugates that
target cell surface antigens, TNT-1 is directed against an intracellular
histone/DNA epitope [5,10], which is present in necrotic and
degeneratingareasoftumorsadjacenttoviabletumorcells.Similarly,
the 7E11 mAb, which is specific for an internal epitope of the
cytoplasmic domain of prostate specific membrane antigen
(PSMA
int), also binds dead cells such as those of the human LNCaP
prostate cancer cell line [11]. However, while
90Y-labeled 7E11 mAb
is ineffective in patients with advanced prostate cancer [12], mAb
targeted to the extracellular domains of PSMA display anti-tumor
activity [13].
In contradistinction to other nuclear antigens, we discovered
that the abundant La ribonucleoprotein (RNP) is overexpressed in
malignancy and actively induced in apoptotic malignant cells in
response to DNA-damaging treatment [14]. During apoptosis, the
La antigen translocates from nucleus to cytoplasm [15], and is
fixed in dying cells by transglutaminase 2 (TG2) [14]. As cell
membrane integrity is lost during the late phase of apoptosis,
cytoplasmic La becomes accessible to binding by specific mAb,
which itself in turn becomes crosslinked in the dying cell by TG2
[14]. Together, these characteristics help to explain the preferen-
tial and antigen-specific tumor targeting of a La-specific mAb in
vivo particularly after cytotoxic chemotherapy [16].
Recently, emerging evidence indicates that impaired clearance of
apoptotic cells or defective ‘waste disposal’ contributes to the
generation of autoantibodies including those with La/SSB specific-
ity in systemic autoimmune diseases such as systemic lupus
erythematosis (SLE) and Sjo ¨gren’s syndrome [17]. Similarly, the
discovery of autoantibodies including La/SSB-specific autoanti-
bodies insera of cancerpatients [18,19] suggeststhat autoantibodies
also arise as a result of inefficient in vivo clearance of dying cancer
cells [20]. Importantly, La-specific antibodies do not appear to have
a direct pathogenic role except in the rare condition of congenital
heart block, which affects the fetuses of 1–2% of pregnant women
who have SLE or Sjo ¨gren’s syndrome [21].
To develop La-targeted radioimmunotherapy, we optimized
conditions for radioimmunoconjugation of the DAB4 clone of the
La-specific mAb, which is represented by the APOMABH
trademark [22]. It is important to note that DAB4 originates
from a murine autoantibody [23]. The antigen-binding domain of
DAB4 has been cloned, sequenced, expressed, and found to bind
with low nanomolar affinity to a La epitope, which is highly
conserved between humans and rodents (Al-Ejeh et al., unpub-
lished data). Here, using murine lymphoma and carcinoma
models, we report therapeutic synergy between La-targeted
radioimmunotherapy and DNA-damaging chemotherapy.
Materials and Methods
Ethics statement
The Animal Ethics Committee of the Institute of Medical and
Veterinary Sciences gave approval for use of the mice. In the use
and care of the mice, we followed the humane research principles
of replacement, reduction and refinement endorsed by the
National Health and Medical Research Council of Australia.
Replacement was not possible because there were no alternative
techniques to tumor-bearing mice. We achieved a reduction in the
numbers of animals used through improved experimental design.
Refinement of procedures to improve the welfare of the animals,
such as use of analgesics, avoiding significant adverse effects, and
enhanced housing conditions, were adopted.
Preparation of radioimmunoconjugates (RIC)
The La-specific murine mAb (DAB4), the prostate membrane
specific antigen (PSMA)-directed mAb (7E11) and their isotype-
matched (IgG2ak) control mAb (Sal5) were conjugated to 1,4,7,10-
tetraazacyclododedane-N,N9,N0,N--tetraacetic acid mono-(N-hy-
droxysuccinimidyl) (DOTA-NHS) ester. DAB4 and Sal5 were
radiolabeled with Indium-111 as described [14,16]. Using
identical conditions, DOTA-mAb conjugates were also radiola-
beled with Yttrium-90. Radio-doses of
90Y-labeled mAb were
determined using the AtomLab100 dose calibrator.
Animal tumor models
The well-characterized EL4 lymphoma model [24] was used as
previously modified [16]. Lewis lung carcinomas (LL2) were
established in 6–8 week old C57BL/6 (B6) mice by injection of 10
6
cells in the right flank. Human prostatic (LNCaP) and pancreatic
(Panc-1) carcinomas were established in 6–8 week old Balb/c nude
mice by injection of 5610
6 cells, which were prepared in 50% v/v
of matrigel in PBS, in the right flank.
Dosimetry calculations
C57BL/6 mice with 1 week-old EL4 tumor implants were
untreated or given 25 mg/kg cyclophosphamide and 19 mg/kg
etoposide (full-dose chemotherapy) by intraperitoneal injection
(i.p.i.).
111In-DOTA-DAB4 was given by intravenous injection
(i.v.i.) in the tail vein to tumor-bearing mice 24 h after
chemotherapy, and an organ assay was performed [16]. Briefly,
radioactivity in counts per minute (cpm) of harvested organs was
divided by the mass to give cpm/g. Then, organ accumulation was
expressed as the injected dose per gram (%ID/g) of tissue, which
was calculated as the percentage of mass-normalized counts to the
total counts (cpm) of
111In-DOTA-DAB4 at time 0. Biodistribu-
tion studies were done using
90Y-DOTA-DAB4 (1.0 MBq). Organ
accumulation was calculated as above, however, radioactivity was
measured by a TriCarb 3000 beta-counter (PerkinElmer Inc.,
Wellesley, MA) using a 15–2000 keV counting window. Area-
under-curve (AUC) values were calculated from time-activity
curves, which were generated from the biodistribution of
111In-
DOTA-DAB4 or
90Y-DOTA-DAB4 over a 96-h analysis period.
Treatment of tumor-bearing mice
Calipers were used to measure the largest (a) and smallest (b)
diameters of the tumors, and tumor volume was calculated
according to the equation: volume=(b
26a)/2. B6 mice bearing EL4
tumors 120–130 mm
3 in volume were given i.p. 9.5 mg/kg
etoposide and 12.5 mg/kg cyclophosphamide (half dose) or
19 mg/kg etoposide and 25 mg/kg cyclophosphamide (full dose).
B6 mice bearing LL2 tumors 50–60 mm
3 in volume were given
i.v. 2.5 mg/kg cisplatin and 50 mg/kg gemcitabine on day 1, and
50 mg/kg gemcitabine on day 2. Balb/c nude mice bearing
LNCaP and Panc-1 tumors 90–100 mm
3 and 50–60 mm
3 in
volume, respectively, were given i.v. 1.0 mg/kg cisplatin on days 1
and 7, and 50 mg/kg gemcitabine on days 1, 4, 7, and 10. RIT
was given by IVI. The specific activities of
90Y–RIC were 65–80
MBq/mg (1.8–2.2 mCi/mg), which were diluted to achieve the
specified doses where the final volume was adjusted to 100 mL
using PBS. The mean doses (6SEM) administered to the mice
weighting 19–21 g were 0.4660.01, 0.9260.02, 1.8060.09,
2.4060.08 and 3.6060.1 MBq (n=5). For combination chemo-
therapy and RIT, RIT was administered 24 h after chemotherapy
for the EL4 tumor model, and on day 3 for the LL2 tumor model.
For the LNCaP and Panc-1 models, RIT was administered on day
2, and the day 10 dose of gemcitabine (50 mg/kg) was omitted to
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survival curves were generated using predefined tumor volumes as
endpoints.
Monitoring of tumor-bearing mice
Mouse weights and tumor volumes were measured every two
days in the first two weeks of treatment and then once a week.
Mice were euthanized immediately by cervical dislocation or CO2
narcosis if a clinical score .3. One point was allocated for each
clinical sign: a) weight loss .15% (cf. day 0) that did not reverse
within 24 h, b) reluctance to move, eat or drink, c) hunched
posture, d) ruffled coat or fur loss, and e) tumor volume .0.5 cm
3
or tumor size that hindered mobility. If $60% of mice in an
experimental group had a clinical score .3 then all mice in the
group were killed and treatment was denoted as toxic.
An independent veterinary pathologist performed necropsies on
EL4 tumor-free mice 61 days after 1.80 and 3.60 MBq
90Y-
DOTA-DAB4 alone, or 0.46 and 0.92 MBq
90Y-DOTA-DAB4
given after chemotherapy (n=2/group). H&E sections of liver,
kidneys, decalcified bone, spleen, small intestine, heart, and lungs
were examined. Necropsies were done at the stated times on LL2
tumor-bearing mice from these experimental groups: control (day
6); chemotherapy alone (day 12);
90Y-DOTA-DAB4 alone at 0.46,
0.92, 1.80 and 3.60 MBq doses on days 6, 6, 7, and 9, respectively;
and chemotherapy combined with
90Y-DOTA-DAB4 at the same
doses on days 12, 15, 17, and 19, respectively (n.2/group). H&E
sections of decalcified bone, lung, heart, small intestine, liver,
spleen or kidney were examined.
Fluorocytometric Analysis of EL4 Lymphoma
Tumors were finely minced with scissors into pieces,10 mm
3,
and a weighed proportion (0.1 g) of tumor mince was suspended in
collagenase Type 1 in Hanks’ Buffered Salt Solution (HBSS)
(10 mL; 2 mg/mL) containing 2.5 mM Ca
2+. Suspensions were
incubated at 37uC with constant rotation for 1 h. Digested tumor
cell suspensions were passed sequentially through a series of
needles (in order of 19G, 23G, and 25G) to remove coarse
materials, and then the last filtrate was centrifuged at 3506g for
5 min. Pellets were washed with HBSS (10 mL), resuspended in
HBSS (1 mL), and aliquots (100 mL) stained for 30 min. at room
temperature (RT) in duplicate with either Sal5 or DAB4 (5 mg/
mL). Cells were washed twice with phosphate buffered saline
(PBS), and incubated with rabbit anti-mouse IgG Alexa488
antibody (2 mg/mL) for 30 min. at RT in the dark. Cells were
washed thrice with PBS, resuspended in 7-Amino-Actinomycin D
(7-AAD) (2 mg/mL), and analyzed 10 min. later using a FACScan
(BD Biosciences, San Jose, CA).
Detergent resistance of residual b-radioactivity in EL4 tumors in
vivo was assayed using single cell suspensions in which aliquots
were incubated for 10 min. at RT with constant shaking in PBS or
a 1% solution of Triton X-100 non-ionic detergent prepared in
PBS. Percent triton X-100-resistant radioactivity was calculated as
the percentage of
90Y-DOTA-DAB4 radioactivity counted in the
triton X-100 sample to that in the PBS sample.
Immunohistochemical detection of biotinylated mAb
and caspase-3 activation
In vivo tumor binding of biotinylated Sal5 or DAB4 mAb was
detected using immunohistochemistry after Sal5-biotin or DAB4-
biotin (100 mg) were given i.v.i. to EL4 tumor-bearing mice, which
were untreated or given 25 mg/kg cyclophosphamide and 19 mg/
kg etoposide. Biotinylated mAb were given i.v.i. 24 h after
chemotherapy and tumors were collected 48 h after biotinylated
mAb injection (i.e. 72 h after chemotherapy). Each tumor was
bisected, and each half embedded in paraffin and sectioned.
Sections were stained with H&E or with 1 mg/mL streptavidin-
horse radish peroxidase (HRP). Entire sections were scanned using
the DotSlide acquisition program (Soft Imaging System, Olympus,
Tokyo, Japan) on a DotSlide BX51 Olympus light microscope
(Olympus) at 206magnification. Scanned sections were visualized
using OlyVIA software (Olympus Viewer for Imaging Applica-
tions) where images of entire tumors or 10 random regions at 106
or 206were obtained for analysis using analySISH software (Soft
Imaging System, Olympus). Phase color analysis was performed
for all images with pixels defining viable cells as blue-counter-
stained nuclei and DAB4-biotin or Sal5-biotin bound cells as
brown staining from DAB deposition.
For immunohistochemical detection of caspase-3 activation,
tumors were collected at the indicated time points, and embedded
and sectioned as described above. Sections were stained with H&E
or with rabbit IgG raised against activated caspase-3 (1 mg/mL;
Chemicon-Millipore, MA) followed by biotin-conjugated anti-
rabbit IgG antibody (1 mg/mL; Rockland Inc., PA) then 1 mg/
mL streptavidin-HRP. Entire sections were scanned using the
DotSlide acquisition program as described above. Phase color
analysis was performed for all images using pixels to define the
different phases: viable cells as blue-counterstained nuclei, apoptotic
cells as brown staining from DAB deposition, and necrotic areas as
faint blue areas lacking appropriate nuclear morphology.
Calculation of tumor doubling time and combination
index
The tumor doubling time (TDT) and combination index (CI)
were calculated using GraphPad Prism v4.0. TDT values were
generated from exponential growth curves, which had been fitted
to % change in tumor volume data (r
2.0.70). Our CI calculations
were adapted [25] to apply to TDT values. First, the TDT value
for untreated mice was subtracted from the TDT value for each
treatment group to obtain ‘blanked’ TDT values (TDTB). Then,
the CI at dose X was calculated as the ratio of TDTB values of
combination treatment to individual treatments: CI at radio-
immunotherapy dose X=(TDTB combination at radioimmu-
notherapy dose X)/(TDTB chemotherapy alone +TDTB radio-
immunotherapy alone at dose X).
Statistical analysis
Statistical analyses was performed with GraphPad Prism v4.0
software. Unless otherwise stated, intergroup comparisons were
made by two-way analysis of variance (ANOVA), with p,0.05
being considered significant. Kaplan-Meier median survival curves
were compared using log-rank (Mantel-Cox) and Gehan-Breslow-
Wilcoxon tests, with p,0.05 being considered significant.
Results
Specificity, safety, and efficacy of La-targeted delivery of
90Y-DOTA-DAB4 to murine EL4 lymphoma grafts in vivo
La is a ubiquitous nuclear antigen, which translocates to
cytoplasm during apoptosis [26] and which is only accessible to
mAb if cells become permeabilized artificially or because of
necrosis or late-stage apoptosis [14]. Therefore, it was necessary to
establish that uptake of DAB4 by dead tumor cells was specific.
First, single EL4 tumor cell suspensions were stained ex vivo with
DAB4 or its Sal5 isotype control of irrelevant Salmonella
specificity, and analyzed by flow cytometry. As shown in
Figure 1A, DAB4 only bound dead tumor cells, and most
noticeably after chemotherapy. Moreover, ex vivo tumor cell
La Is a Cancer Therapy Target
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chemotherapy (Figure 1B). Second, we examined the in vivo
binding tumor cell of DAB4 or Sal5. EL4 tumor-bearing mice
were treated or not with cyclophosphamide/etoposide before
intravenous injections of biotinylated forms of DAB4 or Sal5 were
given. Biotin was then detected in tumor tissue sections (Figure 1C),
and quantification of biotin staining showed that significantly more
DAB4-biotin than Sal5-biotin bound EL4 tumors in vivo,
particularly in tumors of mice given chemotherapy (Figure 1D).
Additional immunofluorescence studies of tumor tissue after in
vivo administration of biotinylated mAb indicated that tumor-
bound DAB4 was intimately related to cells containing cleaved
PARP1, which is recognized as a marker of late apoptosis (Al-Ejeh
et al, accompanying manuscript).
These target characteristics together with the more favorable
biodistribution of DAB4 conferred by delaying DAB4 administra-
tion until 24 hours after chemotherapy (Al-Ejeh et al., accompa-
nying manuscript) suggested that La-directed radioimmunotherapy
may have an improved therapeutic ratio. In particular, to
understand how best to deliver therapeutic doses of DAB4 mAb
labeled with the lethalb-emitting radionuclide,Yttrium-90(
90Y),we
had studied thebiodistribution of radiotracer dosesof
111In-DOTA-
DAB4 in EL4 tumor-bearing mice. These studies indicated that
chemotherapy administered 24 hours before the injection of
111In-
DOTA-DAB4 maximized its tumor uptake and minimized its
uptake by critical organs (Al-Ejeh et al., accompanying manuscript).
We evaluated the safety in EL4 tumor-bearing mice of arming La-
specific DAB4 mAb or its Sal5 isotype control mAb with doubling
doses of
90Y. Irrespective of chemotherapy use, mice receiving up to
the top 3.60 MBq dose of
90Y-DOTA-DAB4 exhibited minimal
toxicity, and none of the mice lost .5% of its starting body weight
(see Figure S1 online). No late complications were discovered in
major organs of tumor-free mice 61 days after treatment.
Antigen-specific targeting of
90Y-radioimmunotherapy was
demonstrated irrespective of chemotherapy use (Figure 2). Al-
though neither 0.46 nor 0.92 MBq
90Y-DOTA-Sal5 altered the
EL4 tumor growth rate, treatment of mice with 0.92 MBq of
90Y-
DOTA-DAB4 significantly retarded tumor growth and increased
Figure 1. Effects of Chemotherapy on Specific EL4 Tumor Cell Binding of DAB4 Binding Ex Vivo and In Vivo. EL4 tumor-bearing mice
(n=5/group) were killed before (0 h) or 24, 48, 72, and 96 h after treatment with 25 mg/kg cyclophosphamide and 19 mg/kg etoposide i.p.i. A,
Single cell suspensions of tumors were stained with 7-AAD and Sal5 or DAB4, and analyzed by flow cytometry. Data shown are representative density
plots for Sal5 or DAB4 binding (x-axis) and cell death measured by 7-AAD (y-axis) at 0 h (Control) or 72 h (Chemo). 7-AAD
+ tumor cells were gated
and the mean fluorescence intensities (MFI) of Sal5 or DAB4 staining of these dead cells are displayed in a time course of representative histograms
from 0 h (control) up to 96 h after chemotherapy. B, Column graph summarizes MFI6SEM (n=5/group) for Sal5 and DAB4 staining of 7-AAD
+ tumor
cells at 0 h (control) or at 72 h post-chemotherapy; *** P,0.001. C, EL4 tumor bearing mice (n=3/group) were untreated or treated with
cyclophosphamide/etoposide as described above. DAB4-biotin or Sal5-biotin (100 mg) were administered i.v.i. 24 h after chemotherapy and tumors
were collected 72 h after chemotherapy (i.e. 48 h after mAb-biotin injection) for immunohistochemical analysis. Representative sections are shown.
Scale bar, 200 mm for the four left-hand panels. Scale bar, 100 mm for the two right-hand panels. D, Image and phase color analysis of tumors (n=3/
group) was performed as described in Methods. Data shown are mean percentage (6SEM) of DAB4
+ cells/total cell number; *** P,0.001.
doi:10.1371/journal.pone.0004630.g001
La Is a Cancer Therapy Target
PLoS ONE | www.plosone.org 4 February 2009 | Volume 4 | Issue 2 | e4630median survival time (MST) from 8 to 14 days (Figure 2A&B). At
higher (1.80 or 3.60 MBq) doses of
90Y-DOTA-DAB4, all mice
(n=5/group) remained tumor-free 61 days after treatment (data
not shown). Moreover, giving the lower (0.46 and 0.92 MBq) doses
of
90Y-DOTA-DAB4 24 hours after chemotherapy rendered 80%
and 100% of mice, respectively, tumor-free 61 days after
treatment (Figure 2C&D), indicating that chemotherapy effectively
reduced the therapeutic dose of
90Y-DOTA-DAB4 by four-fold
(1.80 MBq alone cf. 0.46 MBq with chemotherapy).
Associations of effective treatment in EL4 lymphoma-
bearing mice,
90Y dosimetry, tumor cell death, induction
of La target, and tumor retention of DAB4
Although dosimetry of
111In-DOTA-DAB4 in EL4 tumor-
bearing mice may provide a useful surrogate of
90Y dosimetry
[27], we were surprised to find that, independently of chemother-
apy use, the actual tumor accumulation of
90Y was greater than
that estimated from dosimetry of
111In-DOTA-DAB4 (Table 1).
Therefore, we inferred that La-targeting of
90Y-DOTA-DAB4
begat its own tumor uptake.
To investigate factors underlying this phenomenon, we
analyzed the frequency of tumor cell death. In the 24–48 hours
post-treatment, all therapies yielded a significantly higher
frequency of 7-AAD
+ EL4 tumor cells than observed in control
mice (Figure 3A). Strikingly, curative treatment using
90Y-DOTA-
DAB4 24 hours after chemotherapy produced a cumulative
increase in tumor cell death whereas neither sub-curative
treatment using chemotherapy or 0.92 MBq
90Y-DOTA-DAB4
produced a sustained level of tumor cell death (Figure 3A).
Although analysis of ex vivo binding of DAB4 to dead EL4 tumor
cells confirmed that DNA-damaging chemotherapy induced the
Figure 2. Antitumor Effects in Mice Bearing EL4 Lymphoma, Dose Response, Antigen Specificity, and Chemotherapy Interaction.
EL4 tumor-bearing mice were treated with 19 mg/kg etoposide and 25 mg/kg cyclophosphamide i.p.i. (Chemo) or 0.46 MBq and 0.92 MBq doses i.v.
of
90Y-DOTA-DAB4 or
90Y-DOTA-Sal5 alone or 24 h after chemo (n=5/group). Antitumor effects of Chemo and
90Y-radioimmunoconjugates were
compared. A, Percentage change in mean tumor volume. B, Kaplan-Meier survival analysis was based on the tumor growth endpoint indicated by
dotted line in A. Radioimmunotherapy was antigen-specific because median survival times (MST) were extended from 5 d to 8 d for mice treated with
0.46 MBq DAB4 (P,0.05 versus 0.46 MBq Sal5), and from 8 d to 14 d for mice treated with 0.92 MBq DAB4 (P,0.01 versus 0. 92 MBq Sal5). Antitumor
effects of
90Y-radioimmunoconjugates given 24 h after Chemo were compared. C, Percentage change in mean tumor volume. D, Kaplan-Meier
survival analysis was based on the tumor growth endpoint indicated by dotted line in C. Antigen-specific effects of radioimmunotherapy on survival
were highly significant for 0.46 MBq DAB4 and 0.92 MBq
90Y-DOTA-DAB4 (P,0.001 versus 0.46 and 0.92 MBq
90Y-DOTA-Sal5), by 61 d post-
chemotherapy. Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004630.g002
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90Y-DOTA-DAB4 24 hours after chemo-
therapy augmented ex vivo DAB4 binding significantly more than
either treatment alone (P,0.05) (Figure 3B). Ex vivo tumor
binding of DAB4 was compared with that of TNT1 mAb. Both
mAb bound 7-AAD
+ EL4 cells but only the mean fluorescence
intensity (MFI) of DAB4 binding significantly increased with time
post-chemotherapy whereas TNT1 MFI declined significantly
over time (data not shown).
Since our previous in vitro data indicated that DAB4 became
crosslinked in apoptotic tumor cells [14], we determined if
intratumoral radioactivity was detergent-resistant. After combina-
tion treatment, although significantly more EL4 tumor radioac-
tivity accumulated than with
90Y-DOTA-DAB4 alone (data not
shown), significantly more detergent-resistant radioactivity was
found 96 hours after combination treatment (P,0.001)
(Figure 3C). Since significantly higher splenic accumulation of
90Y-DOTA-DAB4 was detected 48 hours after its injection than
would have been expected from the dosimetry of
111In-DOTA-
DAB4 in control mice (Table 1), splenic accumulation of
90Y-
DOTA-DAB4 may represent progressive trapping of dead
radiolabeled cells by the red pulp of the spleen.
Safety and efficacy of La-targeted delivery of
90Y-DOTA-
DAB4 to syngeneic murine lung carcinoma and human
prostatic and pancreatic cancer cell xenografts in vivo
Next, we turned to relatively radio- and chemo-resistant murine
Lewis lung (LL2), and human prostatic (LNCaP) and pancreatic
(Panc-1) carcinoma models. Chemotherapy produced a small
albeit significant increase in LL2 tumor cell death of 10–15%,
which corresponded to an 8–10% increase in the ratio of activated
caspase-3
+ cells to total cells (Figure 4A). First, we determined that
the maximum tolerated dose (at which no toxicity-related deaths
occurred) was 5.0 MBq for
90Y-DOTA-DAB4 used alone or
24 hours after chemotherapy. Subsequently, we analyzed the
safety and efficacy of
90Y-DOTA-DAB4 alone or with chemo-
therapy. Importantly, no acute pathology was observed in the
major organs of treated LL2 tumor-bearing mice at each of the
indicated time points (dotted line, Figure 4B and C).
Although chemotherapy significantly extended the median
survival time (MST) of LL2 tumor-bearing mice to 12 days
(P,0.01 versus control, 6 days), only the 3.60 MBq dose of
90Y-
DOTA-DAB4 extended MST to 9 days (P,0.05 versus control;
Figure 4B). Antitumor activity of DAB4 depended on
90Y labeling
because 50 mg DAB4-DOTA (equivalent to the mAb mass in 3.60
MBq
90Y-DOTA-DAB4) did not delay tumor regrowth whether it
was used alone or 24 hours after chemotherapy. In contrast and
notwithstanding the relatively low levels of chemotherapy-induced
tumor cell death, 0.92, 1.80, and 3.60 MBq
90Y-DOTA-DAB4
24 hours after chemotherapy extended MST to 15, 17, and 19
days, respectively (P,0.01, P,0.01, P,0.001, respectively, versus
control; Figure 4C).
Since administration of DAB4 24 hours after chemotherapy
enhanced both tumor uptake and clearance from blood and
normal organs (Al-Ejeh et al., accompanying manuscript), we
investigated the therapeutic effects of varying the schedule of
administration (Figure 5). The MST of LL2 tumor-bearing mice
was 22 days when 5.0 MBq
90Y-DOTA-DAB4 was given 24 hours
after chemotherapy compared with 18 days when the dose was
given immediately after chemotherapy (P,0.01; Figure 4B). As
illustrated in Figure 5C, LL2 growth data may also be represented
in the form of a tumor doubling time (TDT), which was a linear
function of
90Y-DOTA-DAB4 dose. While chemotherapy itself
further increased TDT, chemotherapy added to radioimmu-
notherapy augmented the linear dependence of TDT on
90Y-
DOTA-DAB4 dose by 3.0 (60.3)-fold (Figure 5C). Using TDT
values, we calculated a combination index for chemotherapy and
radioimmunotherapy to show that combination treatment using
.0.46 MBq
90Y-DOTA-DAB4 was supra-additive or synergistic
(see Table S1 online).
Finally, we analyzed the interaction between radiosensitizing
cisplatin/gemcitabine chemotherapy and a 2.40 MBq dose of
90Y-
DOTA-DAB4 in two human carcinoma xenograft models. Like
LL2 carcinoma, chemotherapy doubled the frequency of tumor
cell death from 5.360.5% to 10.860.8%, and from 8.260.5% to
1862%, in xenografts of LNCaP and Panc-1 cancer cell lines,
respectively, 72 hours post-treatment. Despite the low-level
chemotherapy-induced tumor cell death in LNCaP tumor-bearing
mice, 2.40 MBq
90Y-DOTA-DAB4 and chemotherapy increased
MST to 15 and 17 days, respectively (P,0.001 versus control, 9
days; Figure 6B). In contrast, 2.40 MBq
90Y-DOTA-7E11, which
is directed against the internal epitope of PSMA expressed by
LNCaP cells, did not extend the MST (10 days) of LNCaP tumor-
bearing mice (Figure 6B). Furthermore, 2.40 MBq
90Y-DOTA-
DAB4 given 24 hours after chemotherapy produced a highly
significant extension of MST to 61 days (P,0.0001 versus control,
and P,0.001 versus any other treatment including 2.40 MBq
90Y-
DOTA-7E11 given 24 hours after chemotherapy; Figure 6B).
In the Panc-1 model, although chemotherapy did not influence
survival, 2.40 MBq
90Y-DOTA-DAB4 extended MST to 31 days
Table 1. Comparison of Treatment Effects on the Relative Biodistribution of
111In-DOTA-DAB4 and
90Y-DOTA-DAB4.
Cumulative organ uptake of DAB4 - mean %ID.g/h (6SEM) for: Treatment group *tumor blood liver
1spleen kidney
c-counts from
111In-label Untreated 1370 (660) 1900 (660) 760 (640) 680 (620) 670 (640)
Chemo 2454 (630) 1820 (6100) 720 (6100) 730 (630) 600 (690)
b-scintillation counts from
90Y-label RIT 1920 (6120) 1910 (640) 840 (640) 950 (640) 830 (660)
ChemoRIT 3400 (6200) 1930 (6100) 850 (640) 960 (640) 830 (630)
EL4 tumor-bearing mice were untreated, or treated with 19 mg/kg etoposide and 25 mg/kg cyclophosphamide chemotherapy i.p.i. Separate experiments were
conducted under similar conditions: 1.0 MBq
111In-DOTA-DAB4 was given i.v.i. to untreated mice or mice 24 h after chemotherapy (Chemo), and 1.0 MBq
90Y-DOTA-
DAB4 was given i.v.i. to mice as radioimmunotherapy (RIT) or to mice 24 h after chemotherapy as ChemoRIT. Organ assays were performed 3, 24, 48, 72, and 96 h after
radioimmunoconjugate injection (n=5 per time point per treatment group). As a measure of cumulative DAB4 uptake, time-activity curves (see Figure S2 online for
detailed organ-specific data) for tumor, blood, liver, spleen, and kidney were used to calculate the mean area under the curve (AUC) for the percentage of injected dose
per gram of tissue per hour (%ID.g/h) (as described in Methods).
*In mice not given Chemo, tumor accumulation of the high-energy b-emitting
90Y significantly exceeded that of the comparable dose of the low-energy c-emitting
111In
(P,0.001). In mice given Chemo, tumor accumulation of
90Y was significantly higher either than that of
111In or of
90Y given as RIT alone (P,0.001).
1Significantly more
90Y-DOTA-DAB4 accumulated in spleens of mice given RIT than in spleens of control mice given a comparable dose of
111In-DOTA-DAB4 (P,0.05).
doi:10.1371/journal.pone.0004630.t001
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90Y-
DOTA-DAB4 24 hours after chemotherapy produced significant
extension of MST to 47 days (P,0.001 versus control, and
P,0.01 versus any other treatment; Figure 6D).
Combination index calculations indicated a distinctly supra-
additive interaction between chemotherapy and DAB4-mediated
radioimmunotherapy in both xenograft models whereas chemo-
therapy synergized modestly with radioimmunotherapy targeted
by PSMA
int-specific 7E11 mAb in the LNCaP model (see Table
S1 online).
Discussion
We have developed a safe and effective means of delivering
systemic cytotoxic chemotherapy and internal ionizing radiation.
The safety of the technology was evident by its lack of clinically
significant acute and late toxicities and its efficacy by clinically
meaningful antitumor activity in mice bearing four different grafts
of lymphoma or carcinoma. The therapeutic effect of La-directed
radioimmunotherapy was antigen-specific and most pronounced
when given after chemotherapy.
In the chemo-responsive [24] and radio-responsive [28] EL4
lymphoma model, we showed that lymphoma-eradicating therapy
depended on either the higher 1.80 and 3.60 MBq doses of
90Y-
DOTA-DAB4 alone or the lower 0.46 and 0.92 MBq doses of
90Y-
DOTA-DAB4 given 24 hours after chemotherapy. This curative
chemoradioimmunotherapy was associated with sustained high
levels of both tumor cell death and ex vivo binding dead tumor cell
binding of DAB4. Conversely, although the components of the
combined therapy individually produced similar extensions of
survival of tumor-bearing mice, neither radioimmunotherapy with
0.92 MBq
90Y-DOTA-DAB4 nor chemotherapy successfully
eradicated lymphoma. In comparison with curative combined
therapy, subcurative lymphoma therapy using either 0.92 MBq
90Y-DOTA-DAB4 or chemotherapy alone induced lower levels of
tumor cell death. Therefore, individual treatment at these doses
may have failed to cure mice because the stabilization or reduction
in tumor cell death at 72–96 hours post-treatment reflected tumor
cell repopulation as well as dissipating cytotoxic activity.
Consequently, we hypothesize that curative lymphoma therapy
depended on a first step of ‘‘target creation’’ that then produced a
Figure 3. Comparisons of Ex Vivo Analyses of Tumor Cell
Death, DAB4 Binding, and Radioactivity in Mice Bearing EL4
Lymphoma. EL4 tumor-bearing mice were untreated (Control), or
treated with 19 mg/kg etoposide and 25 mg/kg cyclophosphamide
i.p.i. alone (Chemo), 0.92 MBq
90Y-DOTA-DAB4 given i.v.i. alone (RIT) or
24 h after chemotherapy (Chemo+RIT). Control and Chemo mice were
given 1.0 MBq
111In-DOTA-DAB4 i.v.i. (24 h after Chemo). A, Compar-
ison of treatment effects on ex vivo FACS analysis of tumor cell death.
Mean percentage 7-AAD
+ dead EL4 tumor cells. As indicated, radio-
immunotherapy produced significantly more tumor cell death at early
time points (**P,0.01, *** P,0.001 versus Control), and Chemo+RIT
induced greater tumor cell death overall (* P,0.05 and *** P,0.001
versus all other treatments). Note that for Chemo+RIT group, Chemo
was given at 224 hour time point on abscissa. B, Comparison of
treatment effects on ex vivo FACS analysis of DAB4 tumor cell binding.
Ex vivo DAB4 binding to 7-AAD
+ dead cells was measured as the net
mean fluorescence intensity (MFI) after subtraction of MFI values for
Sal5 binding (mean of duplicate stains from 3 mice). As indicated, RIT
itself augmented per cell binding of DAB4 (**P,0.05 versus Control),
whereas Chemo+RIT promoted greater DAB4 binding overall (*P,0.05
versus all other treatments). Note that for Chemo+RIT group, Chemo
was given at 224 hour time point on abscissa. C, Effect of
90Y-DOTA-
DAB4 on EL4 tumor cell retention of radioactivity after treatment with
the non-ionic detergent, triton X-100. Mean percentage of detergent-
resistant radioactivity was calculated from the ratio of radioactivity after
triton X-100 treatment to total tumor radioactivity. Chemo+RIT
produced significant retention of tumor radioactivity (P,0.001 versus
RIT alone). Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004630.g003
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LL2 tumor-bearing mice were untreated (Control), or treated i.v.i. with 2.5 mg/kg cisplatin and 50 mg/kg gemcitabine on day 1, and 50 mg/kg
gemcitabine on day 2 (Chemo). Left-hand panel, mean percentage 7-AAD
+ cells in LL2 single tumor cell suspensions (n=3/group). As indicated,
chemotherapy induced significantly more tumor cell death (** P,0.01, *** P,0.001 versus Control). Right-hand panel, percentage of mean number
of activated caspase-3
+ cells divided by total cell number in LL2 tumor sections from Control mice and mice 48 h after Chemo (n=5/group).
Chemotherapy significantly augmented caspase-3 activation (P,0.001 versus Control; two-tailed student’s t-test). B, Comparison of antitumor effects
of chemotherapy and
90Y-DOTA-DAB4. LL2 tumor-bearing mice were untreated (Control), treated i.v.i. either with Chemo as in A or 0.46 MBq, 0.92
MBq, 1.80 MBq, or 3.60 MBq
90Y-DOTA-DAB4 (n=5/group). Left-hand panel, mean percentage change in tumor volume. Right-hand panel, Kaplan-
Meier survival analysis based on the tumor growth endpoint indicated by dotted line in left-hand panel. As indicated, only Chemo and 3.60 MBq
90Y-
DOTA-DAB4 extended survival (*P,0.05, ** P,0.01 versus Control). C, Comparison of antitumor effects of Chemo alone or combined with
90Y-DOTA-
DAB4. LL2 tumor-bearing mice were untreated (Control), treated i.v.i. either with Chemo alone as in A or 0.46 MBq, 0.92 MBq, 1.80 MBq, or 3.60 MBq
90Y-DOTA-DAB4 given 24 h after Chemo (n=5/group). Left-hand panel, mean percentage change in tumor volume. Right-hand panel, Kaplan-Meier
survival analysis based on the tumor growth endpoint indicated by dotted line in left-hand panel. As indicated, 0.92 MBq, 1.80 MBq, and 3.60 MBq
doses of
90Y-DOTA-DAB4 given 24 h after Chemo prolonged survival (**P,0.01, *** P,0.001 versus Chemo). Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004630.g004
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90Y-DOTA-DAB4 binding,
which we have styled as a ‘genotoxic chain reaction’. Our data
suggest that the number of new DAB4 binding targets created by
chemotherapy or radioimmunotherapy derived from an increased
number of dead tumor cells harboring La antigen targets together
with increased availability of La antigen targets in each dead
Figure 5. Antitumor Effects in Mice Bearing LL2 Carcinoma,
90Y-DOTA-DAB4 Schedule, and Chemotherapy Interaction. LL2 tumor-
bearing mice were untreated (Control), treated i.v.i. with 2.5 mg/kg cisplatin and 50 mg/kg gemcitabine on day 1, and 50 mg/kg gemcitabine on day
2 (Chemo d1, 2), or 5.0 MBq of
90Y-DOTA-DAB4 i.v.i. alone on day 3 (5.0 MBq d3) or i.v.i. immediately after Chemo (Chemo d1, 2+5.0 MBq d1) or 24 h
after Chemo on day 3 (Chemo d1, 2+5.0 MBq d3) (n=5/group). A, Mean percentage change in tumor volume. B, Kaplan-Meier survival analysis based
on the tumor growth endpoint indicated by dotted line in A. As indicated, all treatments prolonged survival (**P,0.01, *** P,0.001 versus Control),
but 5.0 MBq
90Y-DOTA-DAB4 was more effective when given 24 h rather than immediately after Chemo (
{ p,0.01). C, Effects of treatments on
doubling times of LL2 tumors. Mean LL2 Tumor Doubling Time (TDT) were derived for treatments outlined in A and B and plotted as a function of
90Y-
DOTA-DAB4 dose for (N) radioimmunotherapy (RIT) alone, (%) RIT immediately after Chemo, or (&) RIT 24 after Chemo. Note that Control and Chemo
only mice received 0 MBq RIT. Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004630.g005
Figure 6. Antitumor Effects in Mice Bearing Human Prostatic or Pancreatic Cell Line Xenografts, Dose Response, and
Chemotherapy Interaction. Balb/c nude mice with established subcutaneous LNCaP or Panc-1 tumors were untreated (Control), treated i.v.i.
with 1.0 mg/kg cisplatin on days 1 and 7, and 50 mg/kg gemcitabine on days 1, 4, 7, and 10 (Chemo), 2.40 MBq of
90Y-DOTA-DAB4 i.v. alone (DAB4),
or 24 h after Chemo (Chemo+DAB4). LNCaP-tumor bearing mice were treated i.v. with 2.40 MBq of
90Y-DOTA-7E11 alone (7E11), or 24 h after Chemo
(Chemo+7E11) (n=5/group). Note that in chemo+RIT groups, day 10 gemcitabine dose was omitted because of previously observed toxicity.
Antitumor effects of
90Y-radioimmunoconjugates on LNCaP xenograft growth were compared. A, Mean percentage change in tumor volume. B,
Kaplan-Meier survival analysis was based on tumor growth endpoint indicated by dotted line in A. As indicated, all treatments except 2.40 MBq
90Y-
DOTA-7E11 prolonged survival (*** P,0.001 versus Control) whereas 2.40 MBq
90Y-DOTA-DAB4 24 h after Chemo prolonged the survival of mice
more than any other treatment including 2.40 MBq
90Y-DOTA-7E11 24 h after Chemo (
1P,0.01). Antitumor effects of chemotherapy and
90Y-DOTA-
DAB4 on Panc-1 xenograft growth were compared. C, Mean percentage change in tumor volume. D, Kaplan-Meier survival analysis was based on the
tumor growth endpoint indicated by dotted line in C. As indicated,
90Y-DOTA-DAB4 alone or after Chemo prolonged survival (*P,0.05, *** P,0.001
versus Control). Error bars for all graphs; 6SEM.
doi:10.1371/journal.pone.0004630.g006
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MBq doses of
90Y-DOTA-DAB4, the number of La antigen
targets present in dead cells of untreated EL4 tumors enabled
initial binding of
90Y-DOTA-DAB4. Subsequently, the radiation
crossfire of the high-energy b-emissions was sufficient to kill
surrounding viable EL4 lymphoma cells, and in turn generated
further rounds of
90Y-DOTA-DAB4 recruitment to the tumor.
Additional support for this hypothesis is drawn from the
observation that EL4 tumors accumulated significantly greater
amounts of
90Y-DOTA-DAB4 than would have been predicted by
the dosimetry of
111In-DOTA-DAB4. Moreover, the finding of
detergent-resistant retention of DAB4-targeted radioactivity in
EL4 tumors only when
90Y-DOTA-DAB4 was given after
chemotherapy rather than by itself suggests that tumor accretion
of DAB4-targeted radioactivity resulted from increased transglu-
taminase 2 activity [14]. We propose that this phenomenon may
be specific to malignant tissue because we did not find any
detergent-resistant accumulation of
90Y-DOTA-DAB4 in normal
tissues after chemotherapy. In particular, although
90Y-DOTA-
DAB4 accumulated significantly more in spleen than expected
from the dosimetry of
111In-DOTA-DAB4, none of this accumu-
lation was detergent-resistant. Finally, recent data from studies of
the immunopathogenesis of congenital heart block in which La-
specific antibodies were shown to inhibit phagocytosis of fetal
cardiomyocytes in vitro [29] suggests that DAB4-mediated
inhibition of the in vivo clearance of DAB4-bound dead tumor
cells may also prolong tumor retention of
90Y-DOTA-DAB4.
In stark contrast to the 70% frequency of chemotherapy-
induced EL4 lymphoma cell death, we found that cisplatin and
gemcitabine chemotherapy approximately doubled tumor cell
death rates among LL2 tumors and human tumor xenografts so
that these rates remained low at clinically relevant levels of #20%
[30]. Nonetheless, we presume that endogenous levels of tumor
cell death were sufficient to enable binding of
90Y-DOTA-DAB4,
which was effective as monotherapy in all carcinoma models. In
addition, administering
90Y-DOTA-DAB4 after chemotherapy
produced greater than additive effects on tumor growth delay and
survival in all carcinoma models, which we hypothesize resulted at
least in part from increased levels of chemotherapy-induced tumor
cell death. Although we have not formally investigated this
possibility, radiosensitizing cisplatin and gemcitabine chemother-
apy may effectively lower the threshold for radiation-induced
carcinoma cell death as suggested for non-cytotoxic doses of
gemcitabine [31]. Hence, future studies will aim to correlate
antitumor effects of combination treatment with measures of
tumor cell death, ex vivo tumor cell binding of DAB4, and tumor
accumulation of DAB4.
We found that combination treatment produced greater
increments in LL2 tumor doubling time than
90Y-DOTA-DAB4
alone. However, despite doubling doses of
90Y-DOTA-DAB4, the
rate of increase in TDT after combination treatment was less than
might be expected. Perhaps, as chemotherapy shrinks the tumor,
the maximum 12 mm tissue penetration depth of
90Y-derived b-
particles results in much of the energy emanating from DAB4-
bound dead tumor cells depositing beyond the confines of the
shrinking tumor. Conversely, the maximum 2.5 mm tissue
penetration depth and the longer physical half-life of Lutetium-
177-derived b-particles suggest that the efficacy of radioimmu-
notherapy dose escalation may be improved if the deposition of
energy within the shrinking LL2 tumor mass is more efficient [32].
Having established preclinical proof-of-concept for La-directed b-
emitting radioimmunotherapy, as a logical extension, we hypoth-
esize that high-energy a-particles originating from a dead-cell
source of a La-bound a-emitting radionuclide will destroy nearby
cancer stem cells in small-volume (#1m m
3) cohesive masses of
metastatic carcinoma [33,34].
Similar to the mechanism proposed for therapeutic synergy in
the EL4 lymphoma model, we propose that the radiosensitizing
chemotherapy facilitated a dose-dependent and self-reinforcing
accretion of
90Y-DOTA-DAB4 in the carcinoma models. In
support of this concept, we found that, irrespective of chemother-
apy use, matched radiation doses of
90Y-DOTA-7E11, which also
targets dead PSMA
int+ LNCaP cells, produced appreciably less
inhibition of LNCaP tumor regrowth than
90Y-DOTA-DAB4.
Therefore, we propose that only binding of dead LNCaP cells by
90Y-DOTA-DAB4 created more targets for its own binding
because antibody-directed b-radiation induced and revealed
significantly more La antigen targets than PSMA
int targets in the
dead LNCaP cells. Interestingly, expression of PSMA may be lost
in LNCaP tumors borne by nude mice after therapeutic
intervention (K, Chester, personal communication, University
College London Cancer Institute, UK).
Although the inherently greater chemo- and radio-sensitivity of
EL4 lymphoma, which is reflected in its brisk and presumably
P53-mediated apoptosis [35], may help to explain EL4 tumor
eradication by the combination of chemotherapy and low doses of
La-directed radioimmunotherapy, other factors may account for
the reduced and differential sensitivity to this combination
treatment of the carcinoma cell lines, LL2, in particular. First,
since the LL2 model is syngeneic, its biological aggressiveness
compared with the LNCaP and Panc-1 xenograft models may
result from the greater compatibility between tumour and host
tissues in a syngeneic model. Second, P53 is mutant in the LL2
[36] and Panc-1 [37] tumors whereas P53 is wild type in the more
treatment responsive LNCaP tumor model [38]. Tumor doubling
time is a third factor to be considered in conjunction with the other
factors, particularly because the LL2 tumor has the shortest
doubling time. The doubling times of untreated LL2, LNCaP, and
Panc-1 tumors were 1.3460.02, 1.8160.01, and 4.4460.02 days,
respectively (see Table S1 online).
Finally, we believe that the schedule of chemo-radioimmu-
notherapy is critically important for both its safety and efficacy.
Our companion studies of the biodistribution of
111In-DOTA-
DAB4 in EL4 lymphoma-bearing mice (Al-Ejeh et al., accompa-
nying manuscript) together with our results using
90Y-DOTA-
DAB4 in LL2 tumor-bearing mice indicate that this chemo-
radioimmunotherapy is safest and most effective if given 24 hours
after chemotherapy rather than immediately after chemotherapy.
When
111In-DOTA-DAB4 was administered 24 hours after
chemotherapy, both its tumor accumulation and blood clearance
were accelerated. In comparision with its administration immedi-
ately after chemotherapy, we found that administering
111In-
DOTA-DAB4 24 hours after chemotherapy resulted in signifi-
cantly reduced accumulation of the radioligand in normal organs
such as the gut (Al-Ejeh et al., accompanying manuscript), which is
particularly susceptible to the cytotoxic effects of chemotherapy or
ionizing radiation.
Although delaying administration of the radioligand accelerated
its blood clearance and thus diminished its blood pool activity in
normal organs, other factors may also account for the reduced
normal organ accumulation of radioligand. For example, studies of
gemcitabine-induced apoptosis of jejunal crypt cells indicate that
apoptosis resolves by 24–36 hours post-treatment [39] perhaps
because, in contrast to the apparently inefficient clearance of cells in
malignant tissues, phagocytosis of apoptotic cells is efficient in
normal tissues [40]. Consequently, we reason that the reduction in
normal organ accumulation of radioactivity observed by delaying
the injection of
111In-DOTA-DAB4 until 24 hours after cytotoxic
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normal tissues such as gut and bone marrow to bystander toxicity
emanating from any
90Y-DOTA-DAB4 bound to apoptotic cells
in these tissues.
Confirmation of the therapeutic relevance of delaying the
injection of the radioligand until 24 hours after chemotherapy was
obtained when
90Y-DOTA-DAB4 administered to LL2 tumor-
bearing mice 24 hours after chemotherapy produced superior
antitumor efficacy compared with its administration immediately
after chemotherapy. Therefore, we hypothesize that scheduling
radioimmunotherapy 24 hours after chemotherapy improves the
therapeutic ratio, and hence the clinical utility, of La-targeted
chemo-radioimmunotherapy because the therapeutic ratio of any
treatment will be improved by reducing its toxicity and/or
increasing its efficacy at a given dose.
In all, we propose that several properties in combination
contribute to the efficiency of La-directed radioimmunotherapy
and make it superior to other previously described mAb therapies
targeting dead cancer cells such as TNT, the antigen target of
which is not induced by DNA-damaging chemotherapy in vitro.
First, La is a universal and high-density target antigen that is
overexpressed in malignant cells. It is also conditionally expressed
in malignant cells by DNA-damaging therapy after dead normal
cells have been cleared, and it appears to be durably retained in
tumors. Second, arming DAB4 mAb with Yttrium-90 generates
bystander killing, and then a self-amplifying recruitment of DAB4
that prolongs tumor retention of DAB4.
Furthermore, the ability of DNA-damaging treatment to create
high tumor densities of La target antigen together with the
prolonged intratumoral retention of DAB4 may extend the utility
of this technology platform to other therapeutic modalities. For
example, antibody-directed enzyme prodrug therapy [41], some
antibody-drug conjugates [42,43], functional nanoparticles [44],
or genetically engineered T-lymphocytes [45], which like radio-
nuclides may amplify therapeutic activity at the target binding site,
can also exert bystander killing of tumor cells lacking the target
antigen.
In conclusion, we provide preclinical proof-of-concept data for a
unique form of systemic chemo-radioimmunotherapy that targets
a universal tumor antigen and subsequently engenders a self-
amplifying method of target creation to elicit a genotoxic chain
reaction. Thus, this technology may meet the challenge of
delivering higher tumor-directed doses of radioimmunotherapy
particularly if used with radiosensitizing agents and/or new classes
of pro-apoptotic agents [46–48]. If applied to treatment of distant
metastases, this approach may deliver systemically the potentially
curative benefits that radiosensitizing chemotherapy and external
beam radiotherapy afford in treatment of locally advanced
carcinomas of the head and neck, esophagus, lung, cervix, and
rectum [49].
Supporting Information
Figure S1 Effects of
90Y-DOTA-DAB4 alone or 24 h after
cyclophosphamide and etoposide chemotherapy on body weight of
EL4 tumor bearing mice. Data shown are percentage change in
mean (6SEM) mouse weights (n=5/group).
Found at: doi:10.1371/journal.pone.0004630.s001 (0.03 MB
DOC)
Figure S2 Biodistribution of
90Y-DOTA-DAB4 and
111In-
DOTA-DAB4 in EL4 Tumor-Bearing Mice. B6 mice bearing
syngeneic EL4 tumors were untreated or treated with full-dose
chemotherapy, and given intravenous injections of
111In-DOTA-
DAB4 (clear columns) or
90Y-DOTA-DAB4 (light gray columns)
alone or
111In-DOTA-DAB4 (dark gray columns) or
90Y-DOTA-
DAB4 (black columns) 24 h after chemotherapy. Mice were killed
at 2, 24, 48, and 72 h after injection of radioimmunoconjugate to
measure its accumulation in blood, main normal organs and
tumors, which was calculated as the percentage of mass-
normalized counts per minute (cpm) to total cpm of the injected
dose at time 0 (%ID/g). Data shown are mean %ID/g6SEM
(n=5/group), *** P,0.001.
Found at: doi:10.1371/journal.pone.0004630.s002 (0.06 MB
DOC)
Table S1 Comparison of Tumor Doubling Time (TDT) and
Combination Index (CI) in A, LL2, B, LNCaP, and C, Panc-1
tumor models. Tumor growth data from control and treated mice
were fitted to exponential growth curves using GraphPad Prism
(v.4.0) to generate tumor doubling times. Data are shown as
mean6SEM. Combination index was calculated as (TDT for
Chemo+RIT2TDT for control)/[(TDT for chemo2TDT for
control)+(TDT for RIT2TDT for control)] e.g. for Chemo
interaction with 0.46 MBq
90Y-DOTA-DAB4, CI=(h-a)/[(g-
a)+(b-a)]. Note that CI.1 indicates supra-additive effects. A, As
described in Figure 4 legend, LL2 tumor-bearing mice were (a)
untreated (Control), treated with (b–f)
90Y-DOTA-DAB4 alone, (g)
Chemo alone, or (h–l)
124 h after Chemo, or (m)
2immediately
after Chemo. B, As described in Figure 5 legend, LNCaP tumor-
bearing mice were (a) untreated (Control), treated with (b)
90Y-
DOTA-7E11 alone, (c)
90Y-DOTA-DAB4 alone, (d) Chemo
alone, or (e)
90Y-DOTA-7E11 24 h after Chemo, or (f)
90Y-
DOTA-DAB4 24 h after Chemo. C, As described in Figure 5
legend, Panc-1 tumor-bearing mice were (a) untreated (Control),
treated with (b)
90Y-DOTA-DAB4 alone, (c) Chemo alone, or (d)
90Y-DOTA-DAB4 24 h after Chemo.
Found at: doi:10.1371/journal.pone.0004630.s003 (0.05 MB
DOC)
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